More than one-third of trial professionals based in the U.S. and Europe believe that digitalization, including the use of real-world evidence, is making trials better, a new survey shows.

Specifically, 39 percent of U.S. and European trial professionals felt that the digitalization of clinical and preclinical trials is improving them, according to a recent GlobalData survey of 131 respondents.

By contrast, only 28 percent of respondents in the Asia-Pacific region think digitalization, which entails the use of emerging technologies, such as artificial intelligence (AI), real-world evidence, application programming interfaces (APIs) and digital platforms, improves trials. This year’s survey results were in line with those seen in both 2019 and 2020, GlobalData said.